Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx Inc
(NQ:
ARDX
)
6.440
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
Next >
Tenapanor for Hyperphosphatemia Approved in Japan
September 25, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
September 11, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 8/30
August 30, 2023
Via
Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/18
April 18, 2023
Via
Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/13
April 13, 2023
Via
Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/5
April 05, 2023
Via
Investor Brand Network
Ardelyx, Inc. Reports Employment Inducement Grants
September 07, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
August 02, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
July 27, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/3
April 03, 2023
Via
Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 3/30
March 30, 2023
Via
Investor Brand Network
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023
Conference call scheduled for 8:00 a.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
July 20, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
July 13, 2023
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
June 29, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
June 05, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
May 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 17, 2023
User Fee Goal Date: October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
May 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 09, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
May 01, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
April 26, 2023
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
April 18, 2023
Company expects to receive goal review date in mid-May
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
April 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
April 12, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 02, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
February 28, 2023
Report focuses on patient access and affordability, workforce wellness and training, community involvement and sound corporate governance
From
Ardelyx, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.